Neural Therapeutics (FRA:M6B) Stock Based Compensation: €0.00 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Stock Based Compensation?

Neural Therapeutics FRA:M6B Stock Based Compensation is €0.00 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Stock Based Compensation for the three months ended in Jan. 2026 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 was €0.00 Mil.

Neural Therapeutics Stock Based Compensation Related Terms

Neural Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Stock Based Compensation Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.26

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Stock Based Compensation of €0.00 Mil mean?
Neural Therapeutics (FRA:M6B) has a Stock Based Compensation of €0.00 Mil as of Jan. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Neural Therapeutics and its competitors.
Is Neural Therapeutics' Stock Based Compensation too high?
Neural Therapeutics' current Stock Based Compensation is €0.00 Mil.
How does Neural Therapeutics' Stock Based Compensation compare to VRTX and REGN?
Neural Therapeutics' Stock Based Compensation of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Neural Therapeutics and its competitors. Neural Therapeutics's current Stock Based Compensation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current Stock Based Compensation of €0.00 Mil. The current Stock Based Compensation is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current Stock Based Compensation is €0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.